Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Sep;280(3):981. doi: 10.1148/radiol.2016164017. No abstract available.

PMID:
27533029
2.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).

Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.

Hepatology. 2016 Oct;64(4):1136-47. doi: 10.1002/hep.28702. Epub 2016 Aug 4.

3.

Sequential Serum Metabolomic Profiling after Radiofrequency Ablation of Hepatocellular Carcinoma Reveals Different Response Patterns According to Etiology.

Goossens C, Nahon P, Le Moyec L, Triba MN, Bouchemal N, Amathieu R, Ganne-Carrié N, Ziol M, Trinchet JC, Sellier N, Diallo A, Seror O, Savarin P.

J Proteome Res. 2016 May 6;15(5):1446-54. doi: 10.1021/acs.jproteome.5b01032. Epub 2016 Apr 14.

PMID:
27015127
4.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Aug;280(2):611-21. doi: 10.1148/radiol.2016150743. Epub 2016 Mar 24. Erratum in: Radiology. 2016 Sep;280(3):981.

PMID:
27010381
5.

Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence.

Petsaris O, Vallet S, Le Guillou-Guillemette H, Veillon P, Gouriou S, Barbier G, Nousbaum JB, Saliou P, NKontchou G, Trinchet JC, Lunel-Fabiani F, Payan C.

J Clin Virol. 2016 Jan;74:19-25. doi: 10.1016/j.jcv.2015.11.011. Epub 2015 Dec 1.

PMID:
26655076
6.

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).

Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Trinchet JC, Moreau R, Roudot-Thoraval F; ANRS CO12 CirVir and Microcir Groups.

Gut. 2017 Feb;66(2):330-341. doi: 10.1136/gutjnl-2015-310275. Epub 2015 Oct 28.

PMID:
26511797
7.

Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.

Cardoso AC, Beaugrand M, de Ledinghen V, Douvin C, Poupon R, Trinchet JC, Ziol M, Bedossa P, Marcellin P.

Ann Hepatol. 2015 Nov-Dec;14(6):826-36. doi: 10.5604/16652681.1171762.

8.

[Diagnosis and initial assessment of cirrhosis].

Trinchet JC, Grando V.

Rev Infirm. 2015 Jan;(207):19-21. doi: 10.1016/j.revinf.2014.10.011. Epub 2014 Dec 29. French.

PMID:
26144509
9.

Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.

Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, Meyer L, Fontaine H, Salmon-Céron D, Samuel D, Seror O, Trinchet JC, Duclos-Vallée JC.

Radiology. 2015 Nov;277(2):443-53. doi: 10.1148/radiol.2015141500. Epub 2015 May 6.

PMID:
25961631
10.

Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.

Godin C, Louandre C, Bodeau S, Diouf M, Saidak Z, Conte MA, Chauffert B, Barbare JC, Barget N, Trinchet JC, Ganne N, Galmiche A.

Anticancer Res. 2015 Mar;35(3):1803-8.

PMID:
25750346
11.

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; ANRS CO12 CirVir Group.

Hepatology. 2015 Sep;62(3):737-50. doi: 10.1002/hep.27743. Epub 2015 Mar 20.

PMID:
25678021
12.

Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Nahon P, Sutton A, Ziol M, Zucman-Rossi J, Trinchet JC, Ganne-Carrié N.

Hepat Oncol. 2015 Jan;2(1):63-78. doi: 10.2217/hep.14.26. Epub 2015 Jan 12. Review.

13.

Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.

Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla DC; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Hepatology. 2015 Feb;61(2):660-7. doi: 10.1002/hep.27546. Epub 2015 Jan 5.

PMID:
25284616
14.

Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O.

Hepat Oncol. 2014 Oct;1(4):395-408. doi: 10.2217/hep.14.22. Epub 2014 Dec 11. Review.

15.

Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?

Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-Ceron D, Meyer L, Trinchet JC, Paule B, Samuel D, Lewin M, Duclos-Vallée JC.

AIDS. 2014 Jun 19;28(10):1379-91. doi: 10.1097/QAD.0000000000000300. Review.

PMID:
24785953
16.

Hepatocellular carcinoma in 2014: current situation and future prospects.

Trinchet JC.

Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):705-8. doi: 10.1016/j.diii.2014.04.005. Epub 2014 Apr 24.

17.

Is segmental transarterial yttrium 90 radiation a curative option for solitary hepatocellular carcinoma ≤5 cm?

Seror O, Nault JC, Nahon P, N'Kontchou G, Trinchet JC.

Hepatology. 2015 Jan;61(1):406-7. doi: 10.1002/hep.27174. Epub 2014 Jun 27. No abstract available.

PMID:
24753142
18.

Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis.

Tarhuni A, Guyot E, Rufat P, Sutton A, Bourcier V, Grando V, Ganne-Carrié N, Ziol M, Charnaux N, Beaugrand M, Moreau R, Trinchet JC, Mansouri A, Nahon P.

J Hepatol. 2014 Aug;61(2):342-50. doi: 10.1016/j.jhep.2014.04.011. Epub 2014 Apr 18.

PMID:
24751829
19.

Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.

Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P.

Hepatology. 2014 Apr;59(4):1471-81. doi: 10.1002/hep.26944. Epub 2014 Feb 25.

PMID:
24677195
20.

Serum 1H-NMR metabolomic fingerprints of acute-on-chronic liver failure in intensive care unit patients with alcoholic cirrhosis.

Amathieu R, Triba MN, Nahon P, Bouchemal N, Kamoun W, Haouache H, Trinchet JC, Savarin P, Le Moyec L, Dhonneur G.

PLoS One. 2014 Feb 19;9(2):e89230. doi: 10.1371/journal.pone.0089230. eCollection 2014.

21.

Histopathologic comparison of monopolar versus no-touch multipolar radiofrequency ablation to treat hepatocellular carcinoma within Milan criteria.

Seror O, N'Kontchou G, Van Nhieu JT, Rabahi Y, Nahon P, Laurent A, Trinchet JC, Cherqui D, Vicaut E, Beaugrand M, Sellier N.

J Vasc Interv Radiol. 2014 Apr;25(4):599-607. doi: 10.1016/j.jvir.2013.11.025. Epub 2014 Feb 12.

PMID:
24529547
22.

ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.

Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N'kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrié N.

J Hepatol. 2013 Dec;59(6):1264-70. doi: 10.1016/j.jhep.2013.07.030. Epub 2013 Aug 6.

PMID:
23928407
23.

Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-52. doi: 10.1158/1055-9965.EPI-13-0179. Epub 2013 Jun 18.

24.

[Screening of hepatocellular carcinoma and surveillance of patients with cirrhosis: a public health issue].

Trinchet JC, Nahon P, Ganne-Carrie N.

Rev Prat. 2013 Feb;63(2):222-5. Review. French.

PMID:
23513790
25.

Diaphragmatic necrosis after radiofrequency ablation of hepatocellular carcinoma: a successful surgical repair.

Kanso F, Nahon P, Blaison D, Trinchet JC, Beaugrand M, Seror O, Martinod E.

Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):e59-63. doi: 10.1016/j.clinre.2012.09.011. Epub 2012 Nov 6.

PMID:
23137756
26.

Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, Seror O, Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L.

Clin Cancer Res. 2012 Dec 15;18(24):6714-22. doi: 10.1158/1078-0432.CCR-12-1099. Epub 2012 Nov 7.

27.

Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients.

Nkontchou G, Tran Van Nhieu J, Ziol M, Tengher I, Mahmoudi A, Roulot D, Bourcier V, Ganne Carrie N, Grando-Lemaire V, Trinchet JC, Cherqui D, Beaugrand M.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):94-8. doi: 10.1097/MEG.0b013e328357cdd7.

PMID:
23085575
28.

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P.

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

PMID:
23069476
29.

Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma.

Couvert P, Carrié A, Tezenas du Montcel S, Vaysse J, Sutton A, Barget N, Trinchet JC, Beaugrand M, Ganne N, Giral P, Chelly J.

Clin Res Hepatol Gastroenterol. 2012 Aug;36(4):345-51. doi: 10.1016/j.clinre.2012.06.013. Epub 2012 Aug 16.

PMID:
22902352
30.

Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.

Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M.

Cancer Prev Res (Phila). 2012 Aug;5(8):1007-14. doi: 10.1158/1940-6207.CAPR-11-0450. Epub 2012 Apr 23.

31.

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.

Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M.

J Viral Hepat. 2012 Apr;19(4):244-53. doi: 10.1111/j.1365-2893.2011.01534.x. Epub 2011 Oct 13.

PMID:
22404722
32.

[Results of percutaneous radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis aged 75 years and over].

Lahbabi M, N'kontchou G, Aout M, Vicaud E, Ganne N, Trinchet JC, Seror O, Beaugrand M.

Rev Med Interne. 2012 Mar;33(3):128-33. doi: 10.1016/j.revmed.2011.12.002. Epub 2012 Jan 4. French.

PMID:
22226387
33.

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).

Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):214-21. doi: 10.1016/j.clinre.2011.11.002. Epub 2011 Dec 19.

PMID:
22189509
34.

Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.

Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P.

J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009. Epub 2011 Dec 13.

PMID:
22173166
35.

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.

Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N'Kontchou G, Beaugrand M, Chevret S; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH).

Hepatology. 2011 Dec;54(6):1987-97. doi: 10.1002/hep.24545.

PMID:
22144108
36.

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M.

J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

PMID:
21914071
37.

A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis.

Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Pessayre D, Beaugrand M.

J Hepatol. 2012 Feb;56(2):426-32. doi: 10.1016/j.jhep.2011.08.010. Epub 2011 Sep 8.

PMID:
21907168
38.

Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study.

Mahmoudi A, Sellier N, Reboul-Marty J, Chalès G, Lalatonne Y, Bourcier V, Grando V, Barget N, Beaugrand M, Trinchet JC, Ganne-Carrié N.

Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):731-7. doi: 10.1016/j.clinre.2011.07.009. Epub 2011 Aug 27.

PMID:
21873139
39.

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.

Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M.

J Clin Endocrinol Metab. 2011 Aug;96(8):2601-8. doi: 10.1210/jc.2010-2415. Epub 2011 Jul 13.

PMID:
21752887
40.

Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis.

N'Kontchou G, Aout M, Laurent A, Nahon P, Ganne-Carrié N, Grando V, Baghad I, Roulot D, Trinchet JC, Sellier N, Cherqui D, Vicaut E, Beaugrand M, Seror O.

J Hepatol. 2012 Jan;56(1):160-6. doi: 10.1016/j.jhep.2011.03.026. Epub 2011 May 19.

PMID:
21703186
41.

Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.

Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Trinchet JC, Beaugrand M, Charnaux N, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1439-46. doi: 10.1158/1055-9965.EPI-11-0341. Epub 2011 May 24.

42.

Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis.

Amathieu R, Nahon P, Triba M, Bouchemal N, Trinchet JC, Beaugrand M, Dhonneur G, Le Moyec L.

J Proteome Res. 2011 Jul 1;10(7):3239-45. doi: 10.1021/pr200265z. Epub 2011 Jun 2.

PMID:
21568267
43.

Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial.

Pateron D, Vicaut E, Debuc E, Sahraoui K, Carbonell N, Bobbia X, Thabut D, Adnet F, Nahon P, Amathieu R, Aout M, Javaud N, Ray P, Trinchet JC; HDUPE Collaborative Study Group.

Ann Emerg Med. 2011 Jun;57(6):582-9. doi: 10.1016/j.annemergmed.2011.01.001. Epub 2011 Feb 17.

PMID:
21333385
44.

Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life.

Trinchet JC.

J Hepatol. 2011 Jun;54(6):1310-1. doi: 10.1016/j.jhep.2010.11.036. Epub 2011 Feb 4. No abstract available.

45.

Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis.

Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne-Carrie N, Grando-Lemaire V, Roulot D, Capeau J, Trinchet JC, Vicaut E, Beaugrand M.

J Hepatol. 2010 Nov;53(5):827-33. doi: 10.1016/j.jhep.2010.04.035. Epub 2010 Jul 14.

PMID:
20728234
46.

Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis?

Nahon P, Sutton A, Pessayre D, Rufat P, Charnaux N, Trinchet JC, Beaugrand M, Deugnier Y.

Antioxid Redox Signal. 2011 Jul 1;15(1):31-8. doi: 10.1089/ars.2010.3529. Epub 2010 Nov 30.

PMID:
20673159
47.

Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail.

Trinchet JC, Beaugrand M.

J Hepatol. 2010 Jul;53(1):23-4. doi: 10.1016/j.jhep.2010.04.002. Epub 2010 Apr 18. No abstract available.

48.

Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis.

Ziol M, Nault JC, Aout M, Barget N, Tepper M, Martin A, Trinchet JC, Ganne-Carrié N, Vicaut E, Beaugrand M, N'Kontchou G.

Gastroenterology. 2010 Jul;139(1):335-43.e2. doi: 10.1053/j.gastro.2010.04.012. Epub 2010 May 20.

PMID:
20399781
49.

[Reactivation of viral hepatitis C during autoimmune hepatitis treated by immunosuppressive agents].

Oudghiri B, Ganne-Carrié N, Grando V, Ziol M, Trinchet JC.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):e12-4. doi: 10.1016/j.gcb.2010.01.012. Epub 2010 Feb 26. French. No abstract available.

50.

Transarterial therapies in HCC: does embolization increase survival?

Forner A, Trinchet JC.

J Hepatol. 2009 Dec;51(6):981-3. doi: 10.1016/j.jhep.2009.09.009. Epub 2009 Sep 30. Review. No abstract available.

Supplemental Content

Loading ...
Support Center